Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions
作者:Haobo Pang、Ye Wang、Fabrice Gallou、Bruce H. Lipshutz
DOI:10.1021/jacs.9b04510
日期:2019.10.30
aromatic or heteroaromatic and an alkyl bromide or iodide leads, in the presence of Zn and a catalytic amount of an Fe(II) salt, to a net reductive coupling. The new C-C bond is regiospecifically formed at rt at the -site of the al-kene. The coupling only occurs in an aqueous micellar medium, where an atypical carbanionic, as opposed to radical, process is likely, supported by several control experiments
在Zn和催化量的Fe(II)盐的存在下,乙烯基取代的芳族或杂芳族和烷基溴或碘的组合导致净还原偶联。新的 CC 键在 rt 在烯烃的 位点区域特异性地形成。偶联仅发生在水性胶束介质中,其中可能是非典型的碳负离子过程,而不是自由基过程,这得到了几个控制实验的支持。提出了一种基于这些数据的机制。
Nickel-Catalyzed Reductive Carboxylation of Styrenes Using CO<sub>2</sub>
作者:Catherine M. Williams、Jeffrey B. Johnson、Tomislav Rovis
DOI:10.1021/ja8062925
日期:2008.11.12
A nickel-catalyzed reductive carboxylation of styrenes using CO2 has been developed. The reaction proceeds under mild conditions using diethylzinc as the reductant. Preliminary data suggests the mechanism involves two discrete nickel-mediated catalytic cycles, the first involving a catalyzed hydrozincation of the alkene followed by a second, slower nickel-catalyzed carboxylation of the in situ formed
已经开发出一种使用 CO2 的镍催化苯乙烯还原羧化反应。使用二乙基锌作为还原剂,反应在温和条件下进行。初步数据表明,该机制涉及两个离散的镍介导的催化循环,第一个涉及烯烃的催化氢化,随后是原位形成的有机锌试剂的第二个较慢的镍催化羧化。重要的是,该催化剂系统非常稳健,即使仅将等摩尔量的二氧化碳引入反应上方的顶部空间,也能以良好的产率固定二氧化碳。
Inhibitors of AKT Activity
申请人:Novartis AG
公开号:US20160287561A1
公开(公告)日:2016-10-06
Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
本发明涉及一种新型杂环羧酰胺化合物,其作为蛋白激酶B活性的抑制剂以及在癌症和关节炎治疗中的应用。
INHIBITORS OF Akt ACTIVITY
申请人:Seefeld Mark A.
公开号:US20100041726A1
公开(公告)日:2010-02-18
Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.